Singtel Innov8 is set to exit cybersecurity technology developer Bitglass in an acquisition deal while Nio Capital contributed to marketing software developer Whale's $50m series B round.

The Duchenne muscular dystrophy drug developer's initial public offering could prove an exit ramp for Roche and Merck & Co.

The Lundbeck, Chiesi Group and Li-Cor Biosciences-backed eye and bladder cancer therapeutics developer has filed to go public on Nasdaq in an offering with a $100m placeholder target.

Mobiliar took part in a $35m round for medicine transportation system developer SkyCell while Nice Investment co-led wealth management software provider Fount's $33.4m series C.

SoftBank is set to achieve an exit as the warehousing robotics technology developer prepares to go public in Oslo on October 20.

Eli Lilly, Taikang and Tencent are in line to exit the diabetes equipment maker, which has filed to go public in Hong Kong next week.

Itochu, Qualcomm, Hearst, Catholic Health Initiatives, TriZetto and IBM are all set to exit the health plan platform developer.

Corporate-backed cloud networking software provider Pluribus pushed its total funding to at least $110m while IAG has exited Hyper Anna in an acquisition by Alteryx.

Quanta Services is contributing to a PIPE deal for the IAC-backed internet service provider’s reverse takeover valuing the combined business at $1.66bn.

Bayer, Pfizer and Ipsen-backed cancer therapeutics developer Pyxis Oncology priced its shares at the top of its range.